Tiagabine-related non-convulsive status epilepticus in partial epilepsy: Three case reports and a review of the literature

Seizure

Volumn 11, Issue 4, 2002, Pages 243-249

  Kellinghaus, Christoph ^a   Dziewas, Rainer ^a   Lüdemann, Peter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

GABA receptor; Non convulsive status epilepticus; Partial epilepsy; Review; Tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; DELTA RHYTHM; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEMALE; FOCAL EPILEPSY; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; VERTIGO;

EID: 0036308692     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2001.0594     Document Type: Article

References (34)

1. Tiagabine
2. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor
3. Safety of tiagabine: Summary of 53 trials
4. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine
5. Tiagabine-induced absence status in idiopathic generalized epilepsy
6. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy
7. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment
8. Tiagabin und nonkonvulsiver status epilepticus
9. Clinical and EEG findings in complex partial status epilepticus with tiagabine
10. Tiagabine and non-convulsive status epilepticus
11. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria
12. Phenytoin-induces seizures: A parodoxical effect at toxic concentrations in epileptic patients
13. Carbamazepine-induced seizures
14. Nonconvulsive status epilepticus
15. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
16. Seizure exacerbation and status epilepticus related to carbamazepine-10, 11-epoxide
17. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin
18. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate
19. Evaluation of the incidence of status epilepticus in association with tiagabine therapy
20. Effects of gamma-aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacosensitive and pharmacoresistant epileptiform activity in vitro
21. Characterisation of tiagabine (NO-238), a new potent and selective GABA uptake inhibitor
22. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier
23. Transport and metabolism of gamma-aminobutyric acid in neurons and glia: Implications for epilepsy
24. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures
25. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats
26. Extracellular GABA in the ventrolateral thalamus of rats exhibiting spontaneous absence epilepsy: A microdialysis study
27. Inhibitory postsynaptic currents or rat substantia nigra pars reticulata neurons: Role of GABA receptors and GABA uptake
28. Baclofen-induced generalized non-convulsive status epilepticus
29. Enhancement of spike and wave discharges by gamma gabamimetic drugs in rats with spontaneous petit-mal like epilepsy
30. Tiagabine in clinical practice-New aspects of efficacy and safety
31. Safety of long-term treatment with tiagabine
32. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat
33. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients
34. Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons